{"id":3233,"date":"2018-10-09T07:15:17","date_gmt":"2018-10-09T11:15:17","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/"},"modified":"2026-09-24T00:09:46","modified_gmt":"2026-09-24T04:09:46","slug":"gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/","title":{"rendered":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs"},"content":{"rendered":"\n<strong>Paris, France, le 9 octobre 2018, 7h30 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0que plusieurs membres de son \u00e9quipe de management pr\u00e9senteront aux conf\u00e9rences suivantes\u00a0:\n\n&nbsp;\n<h3><strong>Chardan 2<sup>nd<\/sup> Annual Genetic Medicines Conference<\/strong><\/h3>\n<strong><em>9 octobre 2018 \u2013 New York (NY, USA)<\/em><\/strong>\n\n<strong>Thomas Gidoin<\/strong>, Chief Financial Officer, et <strong>Barrett Katz<\/strong>, MD, Chief Medical Officer, pr\u00e9senteront le 9 octobre 2018 \u00e0 13h00 ET au Westin New York Grand Central Hotel \u00e0 New York, NY, USA, et tiendront des rendez-vous investisseurs.\n\n&nbsp;\n<h3><strong>Salon Actionaria 2018<\/strong><\/h3>\n<strong><em>22-23 novembre 2018 \u2013 Paris (France)<\/em><\/strong>\n\n<strong>Thomas Gidoin<\/strong>, Chief Financial Officer, et plusieurs membres de l\u2019\u00e9quipe de management viendront \u00e0 la rencontre des actionnaires et investisseurs particuliers les 22 et 23 novembre 2018 au Palais des Congr\u00e8s \u00e0 Paris, France.\n\n<strong>Bernard Gilly<\/strong>, Co-fondateur et Chief Executive Officer, pr\u00e9sentera lors de la tribune \u201c<em>Face aux dirigeants<\/em>\u201d le 22 novembre 2018 \u00e0 15h35 CET, et lors de la tribune \u201c<em>Biotech &amp; Medtech<\/em>\u201d le 22 novembre 2018 \u00e0 17h15 CET.\n\n&nbsp;\n<h3><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 9 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0que plusieurs membres de son \u00e9quipe de management [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,77,80],"post-year":[],"class_list":["post-3233","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-conferences","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 9 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0que plusieurs membres de son \u00e9quipe de management [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-09T11:15:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:46+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs\",\"datePublished\":\"2018-10-09T11:15:17+00:00\",\"dateModified\":\"2026-09-24T04:09:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/\"},\"wordCount\":380,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/\",\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-10-09T11:15:17+00:00\",\"dateModified\":\"2026-09-24T04:09:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/10\\\/09\\\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics","og_description":"Paris, France, le 9 octobre 2018, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0que plusieurs membres de son \u00e9quipe de management [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/","og_site_name":"GenSight Biologics","article_published_time":"2018-10-09T11:15:17+00:00","article_modified_time":"2026-09-24T04:09:46+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs","datePublished":"2018-10-09T11:15:17+00:00","dateModified":"2026-09-24T04:09:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/"},"wordCount":380,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/","name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2018-10-09T11:15:17+00:00","dateModified":"2026-09-24T04:09:46+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/10\/09\/gensight-biologics-invitee-a-presenter-a-plusieurs-conferences-investisseurs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter \u00e0 plusieurs conf\u00e9rences investisseurs"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3233"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3233\/revisions"}],"predecessor-version":[{"id":6464,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3233\/revisions\/6464"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3233"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3233"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3233"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3233"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}